Skip to content
Biodatica
Start free

Parcel Biosciences, Inc.

SAN FRANCISCO, CA · also filed as None

OncologyPhase III
Compare Sign in to watch

What changed

Phase I trial registered: GCC Agonist Signal in the Small Intestine

3mo agoTrial registeredApr 7, 2026Source filing (opens the source filing in a new tab)

Momentum

78no change

Momentum 78 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

~0months

The model puts this company near the end of its last raise.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

672 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Filing

    Form D · $13M

    Mar 4, 2026

    Parcel Biosciences, Inc. · private raise, self-reported by the issuer

    SEC EDGAR · 0002113766-26-000001 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Jan 5, 2023

    Leiomyoma, Uterine · ACTIVE_NOT_RECRUITING · sponsor: Yale University · FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea

    ClinicalTrials.gov · NCT05364008 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Nov 30, 2022

    Barrett Esophagus, Gastroesophageal Reflux Disease, Malignant Digestive System Neoplasm · COMPLETED · sponsor: University of Wisconsin, Madison · GCC Agonist Signal in the Small Intestine

    ClinicalTrials.gov · NCT05107219 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources